Genomics of Drug Sensitivity in Cancer |
Bosutinib
|
Synonyms |
SKI-606, Bosulif
|
Targets |
SRC, ABL, TEC
|
Target pathway |
Other, kinases
|
PubCHEM ID |
5328940
|
Jsmol |
|
Download molecule |
5328940
|
PUBCHEM IUPAC INCHI |
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
|
Smiles |
ClC4(=C(OC)C=C(NC1(=C(C#N)C=NC=2(C1=CC(OC)=C(C=2)OCCCN3(CCN(C)CC3))))C(=C4)Cl)
|
Cluster number |
115
|
calculated LogS |
-5,461
|
Molecular weight |
530,454
|
calculated LogP |
4,5762
|
H-Acceptors |
8
|
H-Donors |
1
|
Ro5 violations |
1
|
Druglikeness |
4,1635
|
DrugScore |
8,40315439282203E-02
|
Mutagenic |
high
|
Tumorigenic |
high
|
Reproductive Effective |
high
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,1422
|
Rat Acute Toxicity |
2,4201
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2+
|
Caco-2 Permeability2 |
1,318
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Strong inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,7152
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Inhibitor
|
Subcellular localization |
Lysosome
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,9938
|